Market News & Trends
FDA Approves Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Limited recently announced the US FDA approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia…
AC Immune Unveils Novel Therapeutic ADC Technology for Improved Efficacy in Neurodegenerative Diseases
AC Immune SA recently unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer Antibody Drug Conjugate) in an oral presentation at the annual…
GeoVax Announces Phase 2 Plans for Cancer Therapy Following Clinical Advisory Committee Review
GeoVax Labs, Inc. recently announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical advisory committee review. GeoVax and…
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease
Vaccinex, Inc. recently announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. Topline results were presented by Eric Siemers,…
GSK Leverages Genedata Biologics as End-to-End Automation & Data Science Platform
Genedata recently announced GSK, a leading biopharma company, has extended the use of Genedata Biologics to new application areas in data sciences, analytics, and R&D automation.…
Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
Ocular Therapeutix, Inc. recently announced the first patients have been enrolled in the Phase 3 SOL-R clinical trial evaluating repeat dosing of AXPAXLI (axitinib intravitreal…
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX2-73 in Fragile X Syndrome (Major Cause of Autism)
Anavex Life Sciences Corp. recently reported positive preclinical results in directly to humans’ translatable biomarkers for individuals with FXS for ANAVEX2-73 (blarcamesine), in a disease…
Dechra Purchases Veterinary Insulin Programs From Akston Biosciences
Dechra Limited and Akston Biosciences Corporation recently announced Dechra’s purchase of all Akston’s interests in the companies’ dog and cat long-acting insulin programs. Dechra’s purchase…
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. OVATION 2 is…
Sapio Sciences & Zifo Announce Strategic Partnership
Sapio Sciences and Zifo recently announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical…
Dosing Completed in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate
Incannex Healthcare Inc. recently announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol (synthetic delta-9-tetrahydrocannabinol…
Bio-Rad Adds Rapid Bispecific Antibody Prototyping & Screening Services to Pioneer Antibody Discovery Platform
Bio-Rad Laboratories, Inc. recently announced the expansion of its Pioneer Antibody Discovery Platform services with the addition of fast generation and screening of bispecific antibodies,…
CordenPharma Invests Nearly One Billion in Transformational Peptide Platform Expansion in the US & Europe
CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology…
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. recently announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for…
Alcami Unveils New Conditions & Services at State-of-the-Art Pharma Storage Facility in Garner
Alcami Corporation has significantly expanded the cold, stability, and custom storage options at its new 65,000 ft2 state-of-the-art pharma storage facility in Garner. With a…
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Lipella Pharmaceuticals Inc. recently announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral…
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison…
Ventyx Biosciences Announces Results From Phase 2 Trial of VTX958 in Participants With Moderately to Severely Active Crohn’s Disease
Ventyx Biosciences, Inc. recently announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn’s…
Alpha Cognition’s Oral Therapy Receives FDA Approval to Treat Alzheimer's Disease
Alpha Cognition recently announced the US FDA has granted approval for ZUNVEYL (benzgalantamine), previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease. Alzheimer’s…
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate
Palisade Bio, Inc. recently announced the successful completion of a microbiome study demonstrating that beta-glucuronidase is present at similar levels among dog, mouse, and human microbiota…
